A Leishmania display platform for expression of human antibodies and glycoproteins

点击翻译按钮获取中文摘要

Immunoprecise Antibodies (IPA) is a Victoria, BC based company with expertise in development andproduction of murine and rabbit monoclonal antibodies (mAbs). To expand its competitive foot print in theantibody and recombinant protein production sector, IPA is exploring new strategies that will provide a morerapid turn around in the production of high quality therapeutic or research antibodies. In the production ofpolyclonal or monoclonal antibodies, one of the most time consuming steps is the immunization and boostingof host animals; which typically requires 50-60 days. To minimize this lag time IPA is interested in developinga new antibody production platform that circumvents the immunization step and will produced full length IgGantibodies that have the correct glycosylation patterns. Implementing this strategy will involve the developmentof an novel bicistronic vectors that will be used to create a surface display IgG library in the protozoanorganism Leishmania. Clones expressing the an IgG antibody that recognizes an antigen of interest can easilybe isolated using a biopanning approach. A major advantage for using Leishmania is that this organism hasglycosylation patterns that closely resemble thos observed on human and rabbit IgG antibodies. This projectwill provide that proof of principle data require for the ultimate creation of a human IgG surface display library.